Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Arcus Biosciences ( (RCUS) ).
Arcus Biosciences, Inc. announced on January 21, 2025, that Dr. Richard Markus will become the Chief Medical Officer effective January 31, 2025, while Dr. Dimitry Nuyten will leave the company on the same date. Dr. Nuyten will receive severance benefits, including a lump-sum payment equivalent to his annual salary, COBRA coverage, and a bonus payment, aligning with the company’s Severance Benefits Plan.
More about Arcus Biosciences
Arcus Biosciences, Inc. operates in the biotechnology industry, focusing on the development of innovative cancer immunotherapies.
YTD Price Performance: -7.27%
Average Trading Volume: 727,842
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.28B
See more data about RCUS stock on TipRanks’ Stock Analysis page.
